⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CLYM News
Climb Bio, Inc. Common Stock
Climb Bio to Present at Upcoming Investor Conferences
globenewswire.com
CLYM
Form 8-K
sec.gov
CLYM
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com
CLYM
Form 8-K
sec.gov
CLYM
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
globenewswire.com
CLYM
Form 8-K
sec.gov
CLYM
Climb Bio, Inc. Announces $110.0 Million Private Placement
globenewswire.com
CLYM
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
globenewswire.com
CLYM
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
globenewswire.com
CLYM
Form 8-K
sec.gov
CLYM